This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Lee H. Harrison, MD
Emory University School of Medicine Atlanta

Claire V. Broome, MD
Centers for Disease Control Atlanta

JAMA. 1989;261(8):1153.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply. —

We congratulate Coles et al on the innovative use of discharge diagnosis data, and we agree with the conclusion that the polysaccharide Haemophilus vaccine provided protective efficacy in children aged 24 to 59 months. A randomized trial of the vaccine in Finland¹ as well as three postlicensure case-control studies^2-4 all demonstrated a protective effect of the vaccine. Only one study,⁵ a small case-control study with wide confidence limits, suggested a lack of efficacy.

Although surveillance data can provide important supporting evidence of efficacy, there are methodological difficulties in using surveillance data to estimate the efficacy of a vaccine, as can be seen in the data presented by Coles et al. Year-to-year variation during the period of 1980 to 1984, when no vaccine was available, was substantial for the two younger age groups, 0 to 23 and 24 to 59 months of age. In fact, . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?